Preamendments Class III devices
This article was originally published in The Gray Sheet
Executive Summary
FDA proposes in the Aug. 18 Federal Register to require premarket approval applications or product development protocols for lung water monitors, powered vaginal muscle stimulators for therapeutic use and stairclimbing wheelchairs. Written comments are due Nov. 16. The agency is also soliciting new information, due Sept. 2, that would justify reclassifying the devices. FDA says that it intends to require regulatory submissions within 90 days of the effective date of the final rule
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.